S&P 500
Nasdaq
Dow Jones
NVDA
AAPL
TSLA
MSFT
BTC-USD
15-min delayed
Live
Home Market News Price Targets Penny Stocks Crypto Economy Commodities Education
Stocks About Contact

Regeneron Pharmaceuticals Inc

REGN XNAS
$714.89 +5.79 (+0.82%) ▲ 15-min delayed
Open
$709.29
High
$717.99
Low
$708.36
Volume
589.0K
Market Cap
$74.95B

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Sector: PHARMACEUTICAL PREPARATIONS Employees: 15.4K Website →

Key Financials

Period Revenue Net Income EPS
Q1 2026 $3.61B $727.20M $6.99
FY 2025 $14.34B $4.50B $43.07
Q3 2025 $3.75B $1.46B $14.09
Q2 2025 $3.68B $1.39B $13.24

Get REGN Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Regeneron Pharmaceuticals Inc.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.